Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury.
Oligodendrocytes (OLs) and their myelin membranes are the apparent injury targets in the putative human autoimmune disease multiple sclerosis. The basis for this selective injury remains to be defined. OLs in vitro have been shown to be susceptible to both tumor necrosis factor (TNF) and non-TNF-dependent immune effector mechanisms. The former involves initial nuclear injury (apoptosis); the latter, when mediated by activated T cells, involves initial cell membrane injury (lysis). In the current study, we determined whether human adult CNS-derived OLs could be protected from the above immune effector mechanisms by selected neurotrophic factors (CNTF, BDNF, NGF, NT-3, and NT-4/5) or cytokines demonstrated to protect from human or experimental autoimmune demyelinating diseases (beta-interferon [IFN], IL-10, and TGF-beta). Nuclear injury was assessed in terms of DNA fragmentation using a DNA nick-end-labelling technique; cell membrane injury was assessed by lactate dehydrogenase or chromium 51 release. MTT and cell counting assays were used to assess cell viability and cell loss, respectively. Amongst the neurotrophic factors and cytokines tested, only CNTF significantly protected the OLs from TNF-mediated injury. CNTF also protected the OLs from serum deprivation-induced apoptosis. CNTF, however, did not protect the OLs from injury induced by activated CD4+ T cells. CNTF also did not protect human fetal cortical neurons from serum deprivation or TNF-induced DNA fragmentation, nor did it protect the U251 human glioma cell line from DNA fragmentation induced by a combination of TNF and reduced serum concentration in the culture media. Our results indicate that potential protective effects of neurotrophic factors or cytokines on neural cell populations can be selective both for cell type involved and mechanism of immune-mediated injury. CNTF is the protective factor selective for nuclear-directed injury of OLs.
D'Souza
S D
SD
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
Alinauskas
K A
KA
Antel
J P
JP
D000328:Adult; D000906:Antibodies; D001921:Brain / Q000166:cytology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D020934:Ciliary Neurotrophic Factor; D003470:Culture Media; D004827:Epilepsy / Q000601:surgery; D005333:Fetus; D005910:Glioma; D006801:Humans; D008233:Lymphotoxin-alpha / Q000494:pharmacology; D009414:Nerve Growth Factors / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D009836:Oligodendroglia / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D011994:Recombinant Proteins / Q000494:pharmacology; D013702:Temporal Lobe / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000633:toxicity*
D000906:Antibodies; D020934:Ciliary Neurotrophic Factor; D003470:Culture Media; D008233:Lymphotoxin-alpha; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha